ArticleAdvanced biomedical research2026
Clinical Findings, Antibody Panel and Pathology of Patients with Inflammatory Myopathies in Isfahan Province, Iran.
Article in Advanced biomedical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the current study, we aimed to evaluate the characteristics of individuals with autoimmune inflammatory myopathies (AIMs) in Isfahan. Material and Methods: In this retrospective, observational study, the clinical, histopathological, immunohistochemical staining, electromyography, and autoantibody profile of the patients with AIM in subgroups of dermatomyositis (DM), necrotizing autoimmune myopathy (NAM), polymyositis (PM), and antisynthetase syndrome (AS) were assessed. Results: Seventy-seven patients with AIMs including 38 (49.3%), 21 (27.3%), 14 (18.2%), and 4 (5.2%) with NAM, DM, PM, and antisynthetase diagnoses were enrolled, respectively. Proximal weakness (94.80%), myalgia (32.46%), skin rash (25.97%), and dysphagia (25.97%) were the most common presentations, among which skin rash was statistically more frequent in DM ( Conclusion: According to the outcomes of the current study, the clinical, histopathological, and autoantibody profiles of the patients with AIM are variably different with remarkable overlaps. Therefore, thorough assessments are required to make the final diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.